ORCID Profile
0000-0002-3721-2432
Current Organisations
Pusan National University
,
Wageningen University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 11-2015
DOI: 10.1016/J.NBD.2015.08.024
Abstract: The hallmarks of Alzheimer disease are amyloid-β plaques and neurofibrillary tangles accompanied by signs of neuroinflammation. Lysozyme is a major player in the innate immune system and has recently been shown to prevent the aggregation of amyloid-β1-40 in vitro. In this study we found that patients with Alzheimer disease have increased lysozyme levels in the cerebrospinal fluid and lysozyme co-localized with amyloid-β in plaques. In Drosophila neuronal co-expression of lysozyme and amyloid-β1-42 reduced the formation of soluble and insoluble amyloid-β species, prolonged survival and improved the activity of amyloid-β1-42 transgenic flies. This suggests that lysozyme levels rise in Alzheimer disease as a compensatory response to amyloid-β increases and aggregation. In support of this, in vitro aggregation assays revealed that lysozyme associates with amyloid-β1-42 and alters its aggregation pathway to counteract the formation of toxic amyloid-β species. Overall, these studies establish a protective role for lysozyme against amyloid-β associated toxicities and identify increased lysozyme in patients with Alzheimer disease. Therefore, lysozyme has potential as a new biomarker as well as a therapeutic target for Alzheimer disease.
Publisher: Elsevier
Date: 2008
Publisher: Elsevier BV
Date: 10-2015
Publisher: Elsevier BV
Date: 12-2010
Publisher: Elsevier BV
Date: 03-2012
Publisher: Elsevier BV
Date: 07-2014
Publisher: Elsevier BV
Date: 12-2011
Publisher: Wageningen University and Research
Date: 27-03-2023
DOI: 10.18174/SESMO.18563
Abstract: Models of socio-environmental or social-ecological systems (SES) commonly address problems requiring interdisciplinary scientific expertise and input from a heterogeneous group of stakeholders. In SES modelling multiple interactions occur on different scales among various phenomena. These scale phenomena include the technical, such as system variables, process detail, inputs and outputs, which most often require spatial, temporal, thematic and organisational choices. From a good practice and project efficiency perspective, the problem scoping and conceptual model formulation phase of modelling is the one to address well from the outset. During this phase, intense and substantive discussions should arise regarding appropriate scales at which to represent the different phenomena. Although the details of these discussions influence the path of model development, they are seldom documented and as a result often forgotten. We draw upon personal experience with existing protocols and communications in recent literature to propose preliminary guidelines for documenting these early discussions about the scale(s) of the studied phenomena. Our guidelines aim to aid modelling group members in building and capturing the richness of their rationale for scoping and scale decisions. The resulting transcripts are intended to promote transparency of modelling decisions and provide essential support for the justification of the final model for its intended use. They also facilitate adaptive modifications of the pathway of model development via retracing decisions and iterative reflection upon alternative scale options.
Publisher: Elsevier BV
Date: 05-2013
Publisher: Elsevier BV
Date: 06-2011
Publisher: Elsevier BV
Date: 04-2011
Location: Switzerland
No related grants have been discovered for Jung Kwan Seo.